Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-24,900
Closed -$248K 1195
2022
Q4
$248K Sell
24,900
-282,800
-92% -$2.55M ﹤0.01% 1073
2022
Q3
$3.68M Buy
307,700
+1,600
+0.5% +$34.4K 0.01% 642
2022
Q2
$9.72M Sell
306,100
-29,900
-9% -$769K 0.04% 447
2022
Q1
$9.27M Buy
336,000
+22,300
+7% +$792K 0.03% 493
2021
Q4
$15.8M Sell
313,700
-29,400
-9% -$1.33M 0.04% 410
2021
Q3
$12.2M Buy
+343,100
New +$13.6M 0.03% 445

Other funds holding XPEV

Axa's XPEV Position: Q1 2023 in Review

Axa sold out of XPeng (XPEV) in Q1 2023, closing a stake of 24,900 shares — an estimated $248K sold.

Axa first reported a position in XPEV in Q3 2021 and held it in 6 quarters. The position peaked at $15.8M in Q4 2021. 221 funds tracked by Wall St. Rank hold XPEV as of Q1 2023.

  • Axa reported no remaining XPeng position as of Q1 2023 after selling out during the quarter.
  • Axa sold 24,900 XPeng shares in Q1 2023, an estimated $248K.
  • Axa first reported a position in XPeng in Q3 2021 and held it in 6 quarters.
  • Axa's XPeng position peaked at $15.8M in Q4 2021.
  • 221 funds tracked by Wall St. Rank held XPeng as of Q1 2023.

Based on Axa's 13F filing for Q1 2023, filed 15 May 2023.